For the year ending 2025-12-31, CHE had -$103,835K decrease in cash & cash equivalents over the period. $325,477K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income | 265,238 |
| Depreciation and amortization | 64,841 |
| Stock option expense | 32,671 |
| Benefit for deferred income taxes | -5,944 |
| Noncash portion of long-term incentive compensation | 4,886 |
| Litigation settlements | 1,425 |
| Noncash directors' compensation | 1,123 |
| Amortization of debt issuance costs | 321 |
| (increase)/decrease in accounts receivable | 11,596 |
| Decrease/(increase) in inventories | -650 |
| (increase)/decrease in prepaid expenses | 844 |
| Decrease in accounts payable and other current liabilities | -5,194 |
| Change in current income taxes | -6,217 |
| Net change in lease assets and liabilities | 806 |
| Decrease/(increase) in other assets | -36,835 |
| Increase in other liabilities | 10,424 |
| Other sources | 459 |
| Net cash provided by operating activities | 388,272 |
| Capital expenditures | 62,795 |
| Proceeds from sale of fixed assets | 4,568 |
| Business combinations, net of cash acquired | 225 |
| Other uses | 888 |
| Net cash used by investing activities | -59,340 |
| Purchases of treasury stock | 431,500 |
| Dividends paid | 31,695 |
| Proceeds from exercise of stock options | 27,152 |
| Change in cash overdraft payable | 10,970 |
| Capital stock surrendered to pay taxes on stock-based compensation | 8,819 |
| Other sources/(uses) | 1,125 |
| Net cash used by financing activities | -432,767 |
| (decrease)/increase in cash and cash equivalents | -103,835 |
| Cash and cash equivalents at beginning of year | 178,350 |
| Cash and cash equivalents at end of year | 74,515 |
CHEMED CORP (CHE)
CHEMED CORP (CHE)